The prospect of FKBP51 as a drug target |
| |
Authors: | Schmidt Mathias V Paez-Pereda Marcelo Holsboer Florian Hausch Felix |
| |
Affiliation: | Max Planck Institute of Psychiatry, Kraepelinstrasse 2-10, 80804 Munich (Germany). |
| |
Abstract: | The FK506 binding protein 51 (FKBP51) is best known as an Hsp90-associated co-chaperone that regulates the responsiveness of steroid hormone receptors. In human genetic association studies, FKBP51 has repeatedly been associated with emotion processing and numerous stress-related affective disorders. It has also been implicated in contributing to the glucocorticoid hyposensitivity observed in New World primates. More recently, several research groups have consistently shown a protective effect of FKBP51 knockout or knockdown on stress endocrinology and stress-coping behavior in animal models of depression and anxiety. The principal druggability of FKBP51 is exemplified by the prototypic FKBP ligands FK506 and rapamycin. Moreover, FKBP51 is highly suited for X-ray co-crystallography, which should facilitate the rational drug design of improved FKBP51 ligands. In summary, FKBP51 has emerged as a promising new drug target for stress-related disorders that should be amenable to drug discovery. |
| |
Keywords: | chaperones drug discovery FK506 immunophilin psychiatric disorders |
本文献已被 PubMed 等数据库收录! |
|